Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes

NCT02562066 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Myasthenic Syndromes, Congenital

Interventions

DRUG: amifampridine phosphate
DRUG: Placebo

Sponsor

Catalyst Pharmaceuticals, Inc.